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Abstract
Background: Long chain omega-3 fatty acids from fish oils (O3) are known to have beneficial effects on a number
of vascular risk factors in at-risk populations. The effects of a highly bioavailable emulsified preparation on an
overweight young adult population are less well known.
Methods: Young adults, age 18–30, with body mass indices (BMIs) greater than 23 (average = 28.1) were
administered 1.7 g of O3 per day (N = 30) or safflower oil placebo (N = 27) in an emulsified preparation (Coromega,
Inc.) for 4 weeks in a double-blind randomized design. Blood was drawn and anthropometric measurements taken
before and after dosing. Hemodynamic measures (central pulse wave velocity, augmentation index, and aortic
systolic blood pressure), inflammatory cytokines (IL-6, IL-8, IL-10, and tumor necrosis factor-α), red blood cell and
plasma phospholipid fatty acid profiles, fasting serum lipids, glucose, and C-reactive protein were measured.
Results: Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations
increased over the four weeks of dosing in the O3 group. Dosing with O3 did not affect central pulse wave
velocity, augmentation index, or aortic systolic blood pressure. None of the five American Heart Association
metabolic syndrome components improved over the dosing period. None of the inflammatory cytokines, C-reactive
protein, or lipids (total or LDL cholesterol) improved over the dosing period.
Conclusions: No salutary effects of O3 were observed in hemodynamic, metabolic syndrome criteria or
inflammatory markers as a result of this relatively short period of administration in this relatively overweight, but
healthy young adult cohort.
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Background
Metabolic syndrome has become highly prevalent in the
U.S. and has a strong impact on the development of future
vascular ailments including Type II diabetes mellitus and
cardiovascular diseases. This increase can be partially at-
tributed to recent changes in the American diet that nega-
tively affect body weight and arterial health [1].
Arterial stiffness is associated with metabolic syn-
drome and is a predictor of cardiovascular events [2].
Pulse wave velocity (PWV) and augmentation index
(AIx) are measurements of arterial distensibility [3].
Reducing dietary saturated fats and increasing omega-3
polyunsaturated fats, especially from fish (O3), have long
been known to improve vascular health and may im-
prove measures of arterial stiffness [4]. Dangardt et al.
reported supplementation with O3s improved vascular
function and lowered the severity of inflammation among
the obese [5]. However, Mackay, et al. found fish oil sup-
plementation among those with or at risk of heart disease
and receiving aspirin and statin therapy had no effect on
pulse wave velocity [6]. O3s have also been found to im-
prove obesity-induced metabolic syndrome through regu-
lating chronic inflammation [7]. These include C-reactive
protein (CRP), interleukin-6 (IL-6), and tumor-necrosis
factor-α (TNF-α) [8].* Correspondence: rootmm@appstate.edu1Department of Nutrition and Health Care Management, Appalachian State
University, Boone, NC 28608, USA
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While previous researchers have focused their studies
on disease risk factors in older at-risk populations [9,10],
the present study sought to investigate the effects of O3
supplementation in a relatively overweight college-aged
population. The pathologies of vascular diseases have
been observed and recorded in the very young. Earlier
intervention in those at early risk may show greater
promise in longer-term benefits. Researchers have found
that younger populations have responded favorably to
O3 dosing during weight loss in reducing triglycerides,
leptin, insulin, insulin resistance, and blood pressure and
increasing ghrelin concentrations [11-14]. In addition,
younger adults tend to consume relatively low amounts
of fish and have relatively low levels of O3s in blood and
tissues [15]. This might make this group especially re-
sponsive to the beneficial effects of even low doses of
O3. Others have also found high PWV and Aix values
among obese adolescents [16]. Thus, this study investi-
gated whether O3s improved arterial health and inflamma-
tory responses, both being indicators of risk for metabolic
syndrome and ultimately, heart disease, diabetes, and
stroke, in a healthy young relatively overweight population.
Methods
Subjects
Healthy 18–30 year old men and women were recruited
from the Appalachian State University student popula-
tion. 430 responded. Respondents were sent a survey to
determine inclusion and exclusion criteria, including
self-reported height and weight and weekly exercise en-
gagement. Of those initial surveys, 343 were returned.
Sixty subjects were invited to participate in the study
based on the following inclusion criteria: body mass
index (BMI) >23 and engagement in regular exercise of
no more than 3 times per week. Subjects were also not
taking any cardiovascular medications or fish oil supple-
ments, not allergic to fish, or with a history of diabetes,
heart disease or a stroke, and did not consume fish more
than twice per week. The research protocol was ap-
proved by the Institutional Review Board of Appalachian
State University.
Study design
The initial treatment and control groups consisted of 30
and 27 participants, respectively. Three subjects who
were invited to enter the study failed to attend the first
clinical visit. Randomization was performed from a ran-
dom digits table. The subjects recruited for this four-
week, double-blind study completed two visits to the
clinic. At the first clinical visit, anthropometric measure-
ments, including height, weight, and waist circumfer-
ence, and seated blood pressure were measured by a
single trained technician. Hemodynamic testing included
central PWV and AIx, which is further used to
determine aortic pressure [17]. Hemodynamic testing
was performed by 3 different trained technicians. A
fasting blood sample was drawn for blood lipids, red
blood cell and plasma phospholipid fatty acid profiles,
high sensitivity C-reactive protein (hsCRP), blood glu-
cose, and inflammatory cytokines. A Health History
Questionnaire was completed at home and returned
within the first week. Participants were requested to
comply with their reported usual exercise habits of three
or less times per week during the study period.
At the conclusion of the first clinical visit, subjects
were supplied with four weeks’ worth of O3 or placebo
oil single-dose packets. Treatment consisted of 4 weeks
of supplementation with O3, 350 mg eicosapentaenoic
acid (EPA) and 230 mg docosahexaenoic acid (DHA) per
single-dose packet, while the placebo was 1.0 g of saf-
flower oil per packet. The oils were emulsified products
(Coromega, Inc., Vista, CA) provided in three premeasured
packets; one packet to be opened and consumed at break-
fast, two packets at dinner. Protocol compliance was moni-
tored with a check sheet that participants kept to record
the supplements they consumed. A second clinical visit oc-
curred at the end of the intervention period of four weeks
and included a second round of clinical measures, blood
draws and hemodynamic testing as before.
Measurements
Height and weight were determined using a Healthometer
(Jarden Corp, Rye, NY) stadiometer and scale. Waist
circumference was measured manually with a tape
measure. Blood pressure was measured using a manual
sphygmometer according to AHA guidelines. Blood
lipids, glucose, and CRP were measured at the local hos-
pital laboratory.
Hemodynamic and vascular testing was performed
with a manual blood pressure cuff and sphygmoman-
ometer and the Sphygmacor Cardiovascular Manage-
ment System. Applanation tonometry (SphygmoCor,
Inc., Sydney, Australia) was used to derive the range of
central arterial indices, including PWV and AIx [17].
The same trained technician preformed each measure-
ment and our laboratory technicians have an intra-class
correlation coefficient of 0.96 with a coefficient of vari-
ation (%CV) of <4.0%.
Serum lipids, glucose, and hsCRP were measured on a
Dimensions RXL instrument from Siemens, Inc. Total
cholesterol was measured by polychromatic endpoint
technique using oxidase, peroxidase and esterase with a
%CV of 1.82%. HDL cholesterol was measured by the
accelerator selective detection method (direct measure
polymer-polyanion) with a 0.92%CV. Triglycerides were
measured by enzyme immunoassay with bichromatic
endpoint with 3.60%CV. LDL cholesterol was measured
by direct measure enzyme immunoassay with bichromatic
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endpoint with 2.72%CV. Glucose was measured by hexo-
kinase with bichromatic endpoint with 3.50%CV. Finally,
hsCRP was measured with colorimetric immunoassay
with bichromatic endpoint with 2.1%CV.
Levels of inflammation protein targets were measured
using the Meso Scale DiscoveryW Multi-SpotW Assay
System. In this multiplex electrochemiluminescent ELISA,
IL-6, IL-8, IL-10, and TNF-α concentrations were detected
on spatially distinct spots in single wells on 96-well plates.
Sample analyses were performed in duplicate. Intra-assay
coefficient of variability between assay plates was 11% for
IL-6, 5% for IL-8, 8% for IL-10, and 7% for TNF-α.
Fatty acid analysis was performed essentially according
to the method of Lands, et al [18]. Briefly, sample lipids
were extracted by the method of Bligh and Dyer [19].
Lipid fractions were separated on thin layer chromatog-
raphy. Appropriate samples were then transesterified
with boron trifluoride and extracted. Methyl esters were
separated and quantified with a Shimadzu capillary gas
chromatograph with flame-ionization detection. Authen-
tic standards and internal standards were used. The %
CVs for the long-chain omega-3 fatty acids were under
5%.
Statistical analysis
Repeated measures general linear models were used to
determine treatment effects. Chi Square and Student t-
tests were used to determine differences between treat-
ment groups at baseline. Analysis was performed with
SPSS v.18 (SPSS, Inc. Chicago, Illinois). A power calcula-
tion was made to estimate group size a priori. A total of
30 subjects were required to give us adequate statistical
power at a p < 0.05 for the outcome variables of PWV
and AIx. Based on existing data from our laboratory, the
estimated sample size of 30 subjects gives us an effect
size of 0.92 and 0.88, respectively, with an alpha set at
0.05. Test-retest reliabilities in our laboratory for these 2
dependent variables are 0.98 and 0.97, respectively.
Results
Of the 57 men and women who entered the study, 51
completed the intervention. Six participants did not re-
turn for the second clinical visit, four from the O3 group
and two from the placebo group. Of those that com-
pleted the study, 41 returned the compliance check
sheets, 19 from the placebo group and 22 from the fish
oil group. Of those, 100% of the placebo participants
consumed greater than 85% of their supplements while
86% of the fish oil participants consumed greater than
85% of their supplements.
Anthropometric measurements and blood samples
were collected during the initial clinical visit. Table 1
summarizes baseline information collected. Subjects chosen
were at risk of metabolic syndrome with blood pressure
measurements and waist circumferences slightly higher
than normal, particularly for women. There were no statis-
tically significant differences in baseline measurements be-
tween the treatment groups.
Measurements were also taken four weeks later, after
O3 supplementation. Figure 1 shows the effect of O3
Table 1 Baseline information of study subjects (percent
or mean ± standard deviation)*
Variable Placebo
group
Omega-3
group
N 27 30
Age (years) 20.4 ± 2.1 21.4 ± 2.9
Female 38% 48%
Body mass index (kg/m2) 27.9 ± 2.9 28.5 ± 3.3
Systolic blood pressure (mmHg) 125 ± 7 124.5 ± 7
Waist circumference, females (cm) 86 ± 10 90 ± 11
Waist circumference, males (cm) 92 ± 8 96 ± 6
Triglycerides (mmol/L) 1.01 ± 0.56 1.01 ± 0.52
HDL-cholesterol (mmol/L) 1.22 ± 0.32 1.20 ± 0.26
Serum glucose (mmol/L) 4.7 ± 0.4 4.7 ± 0.4
Activity level (number times exercise
per week)
3.0 ± 0.9 3.0 ± 0.9
Current Smokers 25% 8%
* None of the groups were statistically significantly different at p < 0.05.
Figure 1 Effect of fish oil supplementation on plasma
phospholipid combined EPA and DHA levels as percent of total
fatty acids before and after treatment.
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dosing for four weeks on plasma phospholipid EPA and
DHA. Plasma levels increased significantly (p < 0.001).
Plasma and red blood cell phospholipid fatty acid out-
comes are displayed in Table 2. Significant increases are
noted for both EPA and DHA and their combination in
both samples. In the plasma the combined EPA and
DHA increased about 80% and in the red blood cells the
combined fatty acids increased about half as much.
The effects of supplementation on components of the
metabolic syndrome, plasma lipids, vascular measures,
and cytokines are shown in Table 3. The daily treatment
dose of 1.7 g of O3 for four weeks had no effect on any
of these measures compared to the safflower placebo.
Not shown are BMI, waist, total cholesterol, serum glu-
cose, IL-8, and IL-10, all of which also showed no effect.
Discussion
In this study we investigated the effect of O3 on rela-
tively overweight but healthy young adults. We found no
effect of 4 weeks of dosing with 1.7 grams per day on
arterial hemodynamic measures, components of the meta-
bolic syndrome, serum lipids, or measures of chronic
inflammation. Yet, we were able to verify a change in O3
status in serum and red cell phospholipids with O3 dosing.
Emulsifying fish oils can enhance digestion and ab-
sorption of the fatty acids. Raatz, et al. investigated
emulsified fish oil absorption compared with capsular
triglyceride fish oil supplements in humans throughout a
48-hour observation period. A single dose (350 mg EPA
and 230 mg DHA) of the emulsified product resulted in
enhanced absorption of total O3 compared with the
capsular supplement. Although we gave a relatively low
dose, Raatz, et al. have shown that this material is
absorbed more quickly and maybe more completely than
fish oil in tablets [20]. Figure 1 shows that the O3 treat-
ment increased plasma O3 EPA and DHA, despite four
apparent non responders in the treatment group and
two with increased EPA and DHA in the placebo group.
Arterial stiffness is associated with metabolic syn-
drome [2]. PWV and pulse pressure are measures posi-
tively associated with aortic stiffening, also measured by
AIx [3,21]. Sjoberg, et al. introduced 2 g, 4 g, and 6 g of
fish oil supplementation per day into the diets of
overweight or obese adults for 12 weeks. Improvement
Table 2 Effect of fish oil supplementation on plasma and red blood cell phospholipid fatty acids*
Markers Placebo Omega-3 Treatment
difference
S.E. of
difference
P-value of
differenceBefore After Before After
Plasma PL% EPA 0.332 0.400 0.329 1.225 +0.832 0.170 p < 0.001
Plasma PL% DHA 1.623 1.370 1.618 2.157 +0.762 0.281 p = 0.008
Plasma PL% EPA&DHA 1.95 1.77 1.95 3.38 +1.61 0.408 p < 0.001
RBC% EPA 0.314 0.373 0.366 1.026 +0.606 0.108 p < 0.001
RBC% DHA 2.930 3.082 3.169 4.169 +0.708 0.245 p = 0.019
RBC% EPA&DHA 3.244 3.455 3.535 5.195 +1.314 0.298 p = 0.002
* Repeated measure general linear models. PL = phospholipid, EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid.
Table 3 Effect of fish oil supplementation on arterial measures*
Markers Placebo Omega-3 Treatment
difference
S.E. of
difference
P-value of
differenceBefore After Before After
Aortic systolic blood pressure (mmHg) 112.1 110.0 110.8 111.1 +2.54 1.70 0.91
Central PWV (m/s) 7.44 6.61 7.49 7.43 +0.76 0.70 0.26
Augmentation Index (%) 10.8 7.4 10.9 11.6 +4.00 2.73 0.47
SBP (mmHg) 125.7 124.5 124.5 125.1 +1.9 1.7 0.26
LDL cholesterol (mmol/L) 2.41 2.39 2.47 2.48 −0.01 0.15 0.81
Triglycerides (mmol/L) 0.88 0.99 0.91 0.91 −0.099 0.145 0.83
HDL-cholesterol (mmol/L) 1.225 1.164 1.204 1.189 +0.004 0.050 0.74
TNF-α (pg/mL) 4.90 4.52 5.31 5.70 +0.14 0.08 0.75
IL-6 (pg/mL) 0.87 0.77 0.99 1.12 +0.21 0.19 0.51
CRP (nmol/L) 20.7 21.8 17.3 18.7 +0.12 0.34 0.53
* Repeated measure general linear models. PWV = Central pulse wave velocity, BMI = Body Mass Index, SBP = Systolic Blood Pressure. TNF-α = Tumor Necrosis
Factor-α, IL-6 = Interleukin-6, CRP = C - reactive protein. Triglycerides, TNF-α, IL-6, and CRP are log transformed; means expressed as geometric means; differences
are expressed as log values.
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in arterial distensibility, as measured by PWV, was only
found to be significant only at the highest dose of 6 g of
fish oil per day [22]. Chong, et al. reported a significant
improvement in PWV and AIx, in healthy adults imme-
diately after a long chain O3 PUFA-rich meal containing
4.7 g of DHA and EPA [4]. However, Sanders, et al. re-
cently found that 1.8 g of EPA and DHA daily over 12 -
months did not improve arterial stiffness among slightly
overweight but relatively healthy middle aged subjects in
England [23]. Thus, using a comparable dose over a
greater duration than in our study within an older age
group yielded similar outcomes.
A number of studies have been conducted on the asso-
ciation between O3 intake and the development of the
metabolic syndrome. The present study found that fish
oils did not have an effect on components of the meta-
bolic syndrome in overweight young adults. Pederson,
et al. found that supplementation with 1.5 g of O3 per
day for 16 weeks significantly lowered systolic blood pres-
sure and raised HDL cholesterol in overweight adolescents
[24]. Also, supplementation with O3 over a 12-week period
significantly lowered serum glucose levels [25].
Inflammation is also recognized as having a significant
relationship with metabolic syndrome [26]. Dietary pat-
terns poor in O3 may cause an excessive production of
pro-inflammatory cytokines and CRP, while causing a
lower production of anti-inflammatory cytokines, all rec-
ognized as contributing to the inflammation associated
with metabolic syndrome and cardiovascular events
[26,27]. Dangardt, et al. executed an intervention of
1.2 g of O3 supplements per day on obese adolescents
for 3 months having an average BMI of 33.8, compared
to our group average BMI of 28.1. Results showed a sig-
nificant decrease in TNF-α and IL-6 levels, but no sig-
nificant change in the serum levels of CRP, IL-8 or IL-10
[5]. Low CRP levels have also been observed in Yup’ik
Eskimos, a population who have mean daily intakes of
DHA and EPA ranging from 2.4 to 3.7 g. In this popula-
tion, CRP blood levels were inversely related to the in-
take of fish oils; however, there was no relationship
found with IL-6 levels and fish oil intake [28]. Our re-
sults, in addition to those found in past studies, may fur-
ther demonstrate the need for a longer intervention
period, a higher treatment dose and an at-risk popula-
tion selection for treatment to observe the desired re-
sults in inflammatory markers.
Overall, our present investigation found little effect of
emulsified fish oil on components of the metabolic syn-
drome, inflammatory cytokines, or hemodynamic mea-
sures of arterial health. Other studies suggest that higher
doses of fish oil coupled with a longer intervention
period executed in a more unhealthy population may be
needed to manifest positive and significant results from
O3 intervention. Strengths of our study include the
bioavailability of the emulsified supplement, clear evidence
for incorporation of O3 doses into blood phospholipids,
the young age of the participants, and the multiplicity of
the endpoints, specifically the hemodynamic markers and
the inflammatory cytokines. However, some limitations to
the study are apparent. These include the short length in
time of the dosing and the relatively low dose compared
to other more recent studies.
Conclusions
The administration of a highly bioavailable emulsified
preparation of fish oil O3 measurably increased plasma
and red blood cells EPA and DHA in four weeks. How-
ever, no beneficial changes were observed in the markers
that were measured for hemodynamic, metabolic syn-
drome, or inflammatory effects as a result in this relatively
healthy overweight young adult cohort. More at-risk pop-
ulations may benefit more from this intervention.
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